Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer.

Mullins CD, Montgomery R, Abernethy AP, Hussain A, Pearson SD, Tunis S; American Society of Clinical Oncology.

J Clin Oncol. 2012 Feb 20;30(6):661-6. doi: 10.1200/JCO.2011.35.5198. Epub 2012 Jan 17.

2.

Lessons learned from independent central review.

Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.

Eur J Cancer. 2009 Jan;45(2):268-74. doi: 10.1016/j.ejca.2008.10.031.

PMID:
19101138
3.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

4.

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.

Stone AM, Bushnell W, Denne J, Sargent DJ, Amit O, Chen C, Bailey-Iacona R, Helterbrand J, Williams G; PhRMA working group.

Eur J Cancer. 2011 Aug;47(12):1763-71. doi: 10.1016/j.ejca.2011.02.011. Epub 2011 Mar 22.

PMID:
21435858
5.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.

J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.

6.

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.

Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM.

Urology. 2001 Apr;57(4 Suppl 1):4-27.

PMID:
11295590
7.

Uncertainty in assessing value of oncology treatments.

Mullins CD, Montgomery R, Tunis S.

Oncologist. 2010;15 Suppl 1:58-64. doi: 10.1634/theoncologist.2010-S1-58.

8.

The NCI All Ireland Cancer Conference.

Johnston PG, Daly PA, Liu E.

Oncologist. 1999;4(4):275-277.

9.

Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.

Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, Harris S.

Clin Trials. 2012 Dec;9(6):671-80. doi: 10.1177/1740774512461859.

PMID:
23250942
10.

Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.

[No authors listed]

Drugs R D. 2005;6(3):178-85. Review.

PMID:
15869322
11.

Reimbursement for cancer treatment: coverage of off-label drug indications.

American Society of Clinical Oncology.

J Clin Oncol. 2006 Jul 1;24(19):3206-8. Epub 2006 May 22.

12.

Accelerated approval of oncology products: the food and drug administration experience.

Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R.

J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21. Review.

13.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

American Society of Clinical Oncology.

J Clin Oncol. 2003 Jun 15;21(12):2397-406. Epub 2003 Apr 11.

PMID:
12692171
14.

Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.

Cheng JS, Lee MJ, Massicotte E, Ashman B, Gruenberg M, Pilcher LE, Skelly AC.

Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S144-63. doi: 10.1097/BRS.0b013e31822ef5b4. Review.

PMID:
21952186
15.
16.

NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.

Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, Howell P, Jahanzeb M, Johnson S, Mackler E, Rubino M, Sarokhan B, Marc Stewart F, Tyler T, Vose JM, Weinstein S, Li EC, Demartino J; NCCN Oncology Risk Evaluation and Mitigation Strategies (REMS) Work Group.

J Natl Compr Canc Netw. 2010 Sep;8 Suppl 7:S7-S27.

PMID:
20947724
17.

Tackling off-label use of anticancer drugs.

Perrone F, de Braud F, Labianca R, Tomino C, Roila F.

J Clin Oncol. 2012 Aug 1;30(22):2800; author reply 2801. doi: 10.1200/JCO.2012.42.9480. Epub 2012 Jul 2. No abstract available.

18.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
19.

Systematic review: reliability of compendia methods for off-label oncology indications.

Abernethy AP, Raman G, Balk EM, Hammond JM, Orlando LA, Wheeler JL, Lau J, McCrory DC.

Ann Intern Med. 2009 Mar 3;150(5):336-43. Epub 2009 Feb 16. Review. Erratum in: Ann Intern Med. 2009 Apr 21;150(8):571.

PMID:
19221366
20.

Methodological recommendations for comparative research on the treatment of chronic wounds.

Sonnad SS, Goldsack JC, Mohr P, Tunis S.

J Wound Care. 2013 Sep;22(9):470-80.

PMID:
24005781
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk